We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+4.91%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$12B
AUM Growth
+$251M
Cap. Flow
-$39.8M
Cap. Flow %
-0.33%
Top 10 Hldgs %
36.53%
Holding
164
New
29
Increased
43
Reduced
30
Closed
27

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$255M
2
BSX icon
Boston Scientific
BSX
+$146M
3
ABBV icon
AbbVie
ABBV
+$121M
4
AGN.PRA
Allergan plc
AGN.PRA
+$109M
5
PBYI icon
Puma Biotechnology
PBYI
+$103M

Top Sells

Rank Stock Value
1
PRGO icon
Perrigo
PRGO
+$207M
2
ZBH icon
Zimmer Biomet
ZBH
+$116M
3
MDVN
MEDIVATION, INC.
MDVN
+$115M
4
ACT.PRA
ACTAVIS PLC Pfd Conv Ser A (Irl)
ACT.PRA
+$105M
5
SYK icon
Stryker
SYK
+$87.8M

Sector Composition

Rank Sector Weight
1 Healthcare 86.53%
2 Financials 0.24%
3 Technology 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIIB icon
1
Biogen
BIIB
$32.1B
$517M 4.32%
1,278,900
+72,100
+6% +$28.9M
BMY icon
2
Bristol-Myers Squibb
BMY
$130B
$516M 4.31%
7,751,100
-1,131,700
-13% -$74.6M
AGN
3
DELISTED
Allergan plc
AGN
$459M 3.83%
1,511,315
-66,872
-4% -$19.9M
HCA icon
4
HCA Healthcare
HCA
$90.7B
$455M 3.8%
5,017,400
+609,400
+14% +$48.8M
ABBV icon
5
AbbVie
ABBV
$471B
$448M 3.74%
6,665,000
+1,850,100
+38% +$121M
CELG
6
DELISTED
Celgene Corp
CELG
$443M 3.7%
3,826,000
+654,000
+21% +$74.8M
AMGN icon
7
Amgen
AMGN
$212B
$442M 3.7%
2,881,000
-168,000
-6% -$26.9M
BSX icon
8
Boston Scientific
BSX
$68.9B
$384M 3.21%
21,680,000
+8,169,000
+60% +$146M
ALXN
9
DELISTED
Alexion Pharmaceuticals
ALXN
$370M 3.09%
2,044,400
+1,478,700
+261% +$255M
GILD icon
10
Gilead Sciences
GILD
$166B
$339M 2.83%
2,895,400
-516,000
-15% -$56.4M
SHPG
11
DELISTED
Shire pic
SHPG
$315M 2.64%
1,306,000
-79,000
-6% -$19.6M
IPXL
12
DELISTED
Impax Laboratories, Inc.
IPXL
$309M 2.59%
6,739,200
+61,200
+0.9% +$2.9M
ICPT
13
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$270M 2.26%
1,120,000
– –
ILMN icon
14
Illumina
ILMN
$29.3B
$251M 2.1%
1,183,228
-53,456
-4% -$10.4M
MOH icon
15
Molina Healthcare
MOH
$10.6B
$245M 2.05%
3,487,900
+28,800
+0.8% +$1.93M
RLYP
16
DELISTED
RELYPSA INC COM
RLYP
$245M 2.05%
7,400,000
-1,457,551
-16% -$50.1M
NBIX icon
17
Neurocrine Biosciences
NBIX
$18.3B
$243M 2.03%
5,094,500
-739,100
-13% -$31.3M
INCY icon
18
Incyte
INCY
$25.3B
$241M 2.02%
2,314,500
-308,000
-12% -$31.9M
HNT
19
DELISTED
HEALTH NET INC
HNT
$237M 1.98%
3,702,200
-159,200
-4% -$9.51M
REGN icon
20
Regeneron Pharmaceuticals
REGN
$73.1B
$236M 1.97%
461,800
+40,000
+9% +$19.5M
COO icon
21
Cooper Companies
COO
$14.2B
$232M 1.94%
5,205,600
+43,600
+0.8% +$1.96M
TMO icon
22
Thermo Fisher Scientific
TMO
$215B
$182M 1.52%
1,402,000
-409,700
-23% -$53.4M
MCK icon
23
McKesson
MCK
$106B
$161M 1.35%
718,000
+5,000
+0.7% +$1.16M
MDVN
24
DELISTED
MEDIVATION, INC.
MDVN
$161M 1.35%
2,826,800
-1,871,000
-40% -$115M
BLUE
25
DELISTED
bluebird bio
BLUE
$161M 1.35%
73,981
+31,467
+74% +$64.1M
1
2 3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q2 2015 Portfolio in Review

As of Q2 2015, OrbiMed held 164 positions worth $12B, up 2.1% from $11.7B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

OrbiMed's Q2 2015 filing shows 29 new, 43 increased, 30 reduced and 27 closed positions. Its largest new stake was Allergan plc: 104,200 shares worth $109M. The largest sale was Perrigo, an estimated $207M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 83% a quarter earlier, followed by Financials and Technology.

  • OrbiMed's largest Q2 2015 buy was Allergan plc: 104,200 shares worth $109M.
  • OrbiMed added most to Alexion Pharmaceuticals in Q2 2015, an estimated $255M increase.
  • OrbiMed's biggest Q2 2015 reduction was Zimmer Biomet, cutting an estimated $116M.
  • OrbiMed fully exited Perrigo in Q2 2015, selling an estimated $207M.
  • OrbiMed's ten largest holdings make up 37% of its $12B portfolio in Q2 2015.
  • OrbiMed opened 29 new positions and closed 27 in Q2 2015.
  • OrbiMed's portfolio value rose 2.1% quarter-over-quarter to $12B.

Based on OrbiMed's 13F filing for Q2 2015, filed 14 Aug 2015.